#United States #San Diego #Robbins LLP #Corcept Therapeutics #CORT

Robbins LLP Urges CORT Stockholders to Connect for Class Action Information

Robbins LLP has renewed its appeal to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT), reminding them of an ongoing class action that impacts all investors who bought or acquired Corcept stock between October 31, 2024, and December 30, 2025. This legal action stems from several allegations regarding misrepresentations made by the company about their promising product candidate, relacorilant.

Corcept is a pharmaceutical firm specializing in treatments for severe medical conditions through the modulation of cortisol, a significant hormone in the body. The company’s leading product candidate, relacorilant, is designed to treat patients suffering from hypercortisolism, commonly known as Cushing's syndrome. During the specified class period, Corcept executives conveyed assurances about the product’s likelihood of receiving FDA approval, suggesting that their clinical trials provided robust support for their New Drug Application (NDA).

Allegations Against Corcept

According to the filed complaint, the defendants at Corcept consistently claimed that they had maintained open communication with the FDA regarding the NDA submission and confidently anticipated the product's approval without facing any obstacles. This narrative suggested a degree of assurance to investors that was undermined by subsequent developments.

As the class period drew to a close, concerns regarding the adequacy of clinical evidence supporting the NDA had been raised, unbeknownst to investors. These concerns were highlighted when, on December 31, 2025, Corcept publicly disclosed that the FDA had issued a Complete Response Letter (CRL). This letter indicated that the FDA could not assess the benefits and risks of relacorilant favorably without further substantial evidence of its effectiveness.

The repercussions were immediate and severe. Following this revelation, Corcept's stock price plummeted, dropping from $70.20 on December 30, 2025, to merely $34.80 the following day—a staggering decline of more than 50%. This sharp decrease underscored the market's reaction to potential misinformation that could have influenced investors' decisions throughout the class period.

What Stockholders Can Do

Shareholders who feel they might be affected by these developments are encouraged to consider participating in the class action against Corcept Therapeutics. Robbins LLP is keen to hear from individuals who wish to step into the role of lead plaintiff, which is crucial for steering the class litigation process. However, participation isn't mandatory to seek restitution—absent class members can opt not to partake but still be eligible for potential recoveries.

Robbins LLP emphasizes that their services are provided on a contingency basis, meaning stockholders will not incur any fees or expenses unless there is a successful recovery.

About Robbins LLP

Founded in 2002, Robbins LLP has established itself as a notable leader in shareholder rights litigation. The firm's focus remains on aiding investors in recovering financial losses, improving corporate governance frameworks, and holding executives accountable for their actions that may harm shareholders.

Interested stockholders can easily seek more information or resources by contacting Robbins LLP through their website. They can also sign up for alerts regarding the progress of this class action or any developments concerning potential misconduct among corporate leaders. By joining forces, shareholders can take a stand against unfair practices and pursue the justice they deserve.

For further assistance or inquiries, investors may submit an online form, contact attorney Aaron Dumas, Jr. via email, or call Robbins LLP directly at (800) 350-6003.